While there are therapeutic strategies emerging to sequester secreted IL-33 using soluble ST2 receptors142, our data provides the provocative notion that targeting nuclear accumulation of IL-33 exclusively may have therapeutic benefit by maintaining a tumor environment with TAMs of a tumor-suppressive phenotype. This evidence concerns the gene IL33 and neoplasm.